198 related articles for article (PubMed ID: 27410928)
21. [Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study].
Galy G; Labidi SI; Tissier F; Combes JD; Auger A; Favier B; Latour JF
Bull Cancer; 2009 Feb; 96(2):141-5. PubMed ID: 19258220
[TBL] [Abstract][Full Text] [Related]
22. Why do we need another antiemetic? Just ask.
Kris MG
J Clin Oncol; 2003 Nov; 21(22):4077-80. PubMed ID: 14559888
[No Abstract] [Full Text] [Related]
23. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.
Wang X; Wang L; Wang H; Zhang H
Cell Biochem Biophys; 2015 Jun; 72(2):471-3. PubMed ID: 25567657
[TBL] [Abstract][Full Text] [Related]
25. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
[TBL] [Abstract][Full Text] [Related]
26. [Prevention of nausea and vomiting. Aprepitant, the first therapeutic acting NK-1 receptor antagonist].
Nieber K; Schoppmeyer K
Pharm Unserer Zeit; 2007; 36(5):373-80. PubMed ID: 17722144
[No Abstract] [Full Text] [Related]
27. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
28. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
29. Japanese patients equally likely to benefit from aprepitant for chemotherapy-induced nausea and vomiting prevention.
da Silveira Nogueira Lima JP; Nakamura RA; dos Santos LV
Cancer Sci; 2011 May; 102(5):1112; author reply 1113. PubMed ID: 21492319
[TBL] [Abstract][Full Text] [Related]
30. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
31. [The prevention of nausea and vomiting induced by antineoplastic chemotherapy: the state of the art].
Roila F; Tonato M; Del Favero A
Riv Inferm; 1991; 10(1):40-3. PubMed ID: 1853098
[No Abstract] [Full Text] [Related]
32. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
[TBL] [Abstract][Full Text] [Related]
33. Neurokinin antagonism and chemotherapy-induced emesis.
Shanahan F; O'Sullivan GC
Am J Gastroenterol; 1999 Nov; 94(11):3368-9. PubMed ID: 10566748
[No Abstract] [Full Text] [Related]
34. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann CH; Herrstedt J
Expert Opin Drug Saf; 2011 May; 10(3):449-62. PubMed ID: 21417835
[TBL] [Abstract][Full Text] [Related]
35. [Trial with a new anti-nausea regime].
Midgaard T
Fag Tidsskr Sykepleien; 1990 Nov; 78(8):15, 29. PubMed ID: 2271331
[No Abstract] [Full Text] [Related]
36. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
Navari RM; Gray SE; Kerr AC
J Support Oncol; 2011; 9(5):188-95. PubMed ID: 22024310
[TBL] [Abstract][Full Text] [Related]
37. Protracted cisplatin-induced vomiting responding to mosapride.
Ganesan P; Sharma A; Mohanti BK; Gogia A
Indian J Cancer; 2010; 47(1):73-4. PubMed ID: 20071797
[No Abstract] [Full Text] [Related]
38. Oral ondansetron for preventing nausea and vomiting.
Cooke CE; Mehra IV
Am J Hosp Pharm; 1994 Mar; 51(6):762-71. PubMed ID: 8010314
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.
Jordan K; Kasper C; Schmoll HJ
Eur J Cancer; 2005 Jan; 41(2):199-205. PubMed ID: 15661543
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
Nakade S; Ohno T; Kitagawa J; Hashimoto Y; Katayama M; Awata H; Kodama Y; Miyata Y
Cancer Chemother Pharmacol; 2008 Dec; 63(1):75-83. PubMed ID: 18317761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
